Panel notes mention need for a 2nd trial. Anyone who left a job to join Aveo must be freaking out. My guess is close vote, but leadership team chooses to abandon commercial operations. This market is small and overcrowded. Good luck.
Even if this drug gets approved the bad pub with lower OS than Nexavar is going to be very tough to overcome in the firstline setting versus Sutent.
Heading towards a close no vote at ODAC. Management should have been bold and went head to head against sutent in the first place.
Don't worry. No one actually responsible for this failure will suffer. Instead, the axe will fall on multiple, peon heads so that the BoD and execs can keep their wealth.
Several reasons for start failures but the number one reason, they hire there buddies instead of hiring people who know what to do and how to do it.
